JP Morgan Chase’s Myovant Sciences Ltd. MYOV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-53,492
Closed -$1.44M 7470
2022
Q4
$1.44M Sell
53,492
-134,022
-71% -$3.53M ﹤0.01% 3814
2022
Q3
$3.37M Sell
187,514
-46,877
-20% -$748K ﹤0.01% 3063
2022
Q2
$2.91M Buy
234,391
+218,733
+1,397% +$2.41M ﹤0.01% 3245
2022
Q1
$208K Buy
15,658
+830
+6% +$11.1K ﹤0.01% 5173
2021
Q4
$230K Buy
14,828
+1,360
+10% +$26K ﹤0.01% 5276
2021
Q3
$302K Buy
13,468
+312
+2% +$6.85K ﹤0.01% 5013
2021
Q2
$299K Buy
13,156
+860
+7% +$18.1K ﹤0.01% 5018
2021
Q1
$253K Buy
12,296
+9,140
+290% +$208K ﹤0.01% 5056
2020
Q4
$87K Buy
3,156
+461
+17% +$8.97K ﹤0.01% 5036
2020
Q3
$42K Sell
2,695
-393
-13% -$7.31K ﹤0.01% 4993
2020
Q2
$63K Sell
3,088
-1,308
-30% -$17.8K ﹤0.01% 4748
2020
Q1
$34K Sell
4,396
-2,011
-31% -$22.6K ﹤0.01% 4835
2019
Q4
$99K Sell
6,407
-249,170
-97% -$2.51M ﹤0.01% 4906
2019
Q3
$1.33M Buy
255,577
+143,216
+127% +$1.06M ﹤0.01% 3674
2019
Q2
$1.04M Buy
112,361
+28,941
+35% +$432K ﹤0.01% 3845
2019
Q1
$1.99M Sell
83,420
-38,444
-32% -$786K ﹤0.01% 3334
2018
Q4
$2M Buy
121,864
+30,269
+33% +$597K ﹤0.01% 3274
2018
Q3
$2.43M Sell
91,595
-32,068
-26% -$726K ﹤0.01% 3318
2018
Q2
$2.83M Buy
123,663
+16,719
+16% +$365K ﹤0.01% 3138
2018
Q1
$2.27M Buy
106,944
+6,263
+6% +$95.3K ﹤0.01% 3183
2017
Q4
$1.27M Buy
100,681
+9,468
+10% +$127K ﹤0.01% 3581
2017
Q3
$1.38M Buy
91,213
+14,203
+18% +$173K ﹤0.01% 3350
2017
Q2
$901K Sell
77,010
-6,060
-7% -$75.1K ﹤0.01% 3481
2017
Q1
$975K Buy
83,070
+19,474
+31% +$223K ﹤0.01% 3431
2016
Q4
$791K Buy
+63,596
New +$737K ﹤0.01% 3548

Other funds holding MYOV

JP Morgan Chase's MYOV Position: Q1 2023 in Review

JP Morgan Chase sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 53,492 shares — an estimated $1.44M sold.

JP Morgan Chase first reported a position in MYOV in Q4 2016 and held it in 25 quarters. The position peaked at $3.37M in Q3 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • JP Morgan Chase reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • JP Morgan Chase sold 53,492 Myovant Sciences Ltd. shares in Q1 2023, an estimated $1.44M.
  • JP Morgan Chase first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 25 quarters.
  • JP Morgan Chase's Myovant Sciences Ltd. position peaked at $3.37M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.